CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population

Figures & data

Table 1 Genotype and allele distribution of two single-nucleotide polymorphism loci in patients with non-small-cell lung cancer and normal controls

SNP genotype/allele	Patients n=302 (%)	Controls n=389 (%)	P-value	OR (95% CI)
rs763361 genotype
CC	84 (27.8)	151 (38.8)	Ref	Ref
CT	166 (55.0)	194 (49.9)	0.012a	1.98 (1.42–2.75)
TT	52 (17.2)	44 (11.3)	<0.001a	2.73 (1.70–4.39)
Allele
C	334 (55.3)	496 (63.8)	0.001a	1.42 (1.14–1.77)
T	270 (44.7)	282 (36.2)
rs727088 genotype
AA	109 (36.1)	218 (56.0)	Ref	Ref
AG	163 (54.0)	158 (40.6)	<0.001a	2.06 (1.50–2.83)
GG	30 (9.9)	13 (3.3)	<0.001a	4.62 (2.31–9.20)
Allele
A	381 (63.1)	594 (76.3)	<0.001a	1.89 (1.50–2.39)
G	223 (36.9)	184 (23.7)

Notes:

a Statistically significant.

Abbreviations: OR, odds ratio; CI, confidence interval; SNP, single-nucleotide polymorphism; n, number of patients or controls; Ref, reference.

Table 2 Association between clinical characteristics of patients with non-small-cell lung cancer and polymorphism of locus rs763361

Characteristics	Patients,n	Genotype, n (%)			P-value	Allele no (%)		P-value	OR (95% CI)
		CC	CT	TT		C	T
Sex
Female	86	26 (30.2)	51 (59.3)	9 (10.5)	0.161	103 (59.5)	69 (40.1)	0.155	1.30 (0.91–1.86)
Male	216	57 (26.4)	115 (53.2)	42 (19.4)		229 (53.5)	199 (46.5)
Age
≤60 years	171	47 (27.5)	95 (55.6)	29 (16.9)	0.830	189 (55.3)	153 (44.7)	0.984	0.99 (0.72–1.38)
>60 years	131	37 (28.2)	71 (54.2)	23 (17.6)		145 (55.3)	117 (44.7)
Histological type
ADC	138	44 (31.9)	75 (54.3)	19 (13.8)		163 (59.1)	113 (40.9)
SCC	138	33 (23.9)	77 (55.8)	28 (20.3)	0.190	143 (51.8)	133 (48.2)	0.087	1.34 (0.96–1.88)
Others	26	7 (26.9)	14 (53.8)	5 (19.2)	0.733	28 (53.8)	24 (46.2)	0.485	1.24 (0.68–2.24)
Differentiation
Poor	204	59 (28.9)	111 (54.4)	34 (16.7)	0.809	229 (56.1)	179 (43.9)	0.554	1.11 (0.79–1.56)
Moderate–well	98	25 (25.5)	55 (56.1)	18 (18.4)		105 (53.6)	91 (46.4)
Tumor size
T1	34	11 (32.4)	17 (50.0)	6 (17.6)		39 (57.4)	29 (42.6)
T2	192	53 (27.6)	106 (55.2)	33 (17.2)	0.828	212 (55.2)	172 (44.8)	0.743	1.09 (0.65–1.84)
T3	51	15 (29.4)	27 (52.9)	9 (17.6)	0.955	57 (55.9)	45 (44.1)	0.850	1.60 (0.57–1.97)
T4	25	5 (20.0)	16 (64.0)	4 (16.0)	0.512	26 (52.0)	24 (48.0)	0.563	1.24 (0.58–2.59)
Lymph node
N0	156	43 (27.6)	83 (53.2)	30 (19.2)		170 (54.1)	144 (45.7)
N1	107	36 (33.6)	56 (52.3)	15 (14.0)	0.407	128 (59.8)	86 (40.2)	0.197	0.79 (0.56–1.13)
N2	38	5 (13.2)	26 (68.4)	7 (18.4)	0.147	36 (47.4)	40 (52.6)	0.289	1.31 (0.79–2.17)
Metastasis
M0	285	78 (27.4)	157 (55.1)	50 (17.5)	0.709	313 (54.9)	257 (45.1)	0.435	0.75 (0.37–1.54)
M1	17	6 (35.3)	9 (52.9)	2 (11.8)		21 (61.8)	13 (38.2)
Clinical stage
I + II	223	67 (30.0)	116 (52.0)	40 (17.9)	0.209	250 (56.1)	196 (43.9)	0.577	0.89 (0.62–1.28)
III + IV	79	17 (21.5)	50 (63.3)	12 (15.2)		84 (53.2)	74 (46.8)

Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval.

Table 3 Association between clinical characteristics of patients with non-small-cell lung cancer and polymorphism of locus rs727088

Characteristics	Patients, n	Genotype n (%)			P-value	Allele n (%)		P-value	OR (95% CI)
		AA	AG	GG		A	G
Sex
Female	86	34 (39.5)	43 (50.0)	9 (10.5)	0.677	111 (64.5)	61 (35.5)	0.640	1.09 (0.76–1.58)
Male	216	75 (34.7)	120 (55.6)	21 (9.7)		270 (65.5)	162 (37.5)
Age
≤60 years	170	63 (37.1)	91 (53.5)	16 (9.4)	0.895	217 (63.8)	123 (36.2)	0.667	1.08 (0.77–1.50)
>60 years	132	46 (34.8)	72 (54.5)	14 (10.6)		164 (62.1)	100 (37.9)
Histological type
ADC	1,381	49 (35.5)	75 (54.3)	14 (10.1)		173 (62.7)	103 (37.3)
SCC	138	47 (34.1)	77 (55.8)	14 (10.1)	0.967	171 (62.0)	105 (38.0)	0.861	1.03 (0.73–1.46)
Others	26	13 (50.0)	11 (42.3)	2 (7.7)	0.376	37 (71.2)	15 (28.8)	0.364	0.68 (0.36–1.30)
Differentiation
Poor	204	72 (35.3)	111 (54.4)	21 (10.3)	0.898	255 (62.5)	153 (37.5)	0.670	0.93 (0.65–1.32)
Moderate–well	98	37 (37.8)	52 (53.1)	9 (9.2)		126 (64.3)	70 (35.7)
Tumor size
T1	34	16 (47.1)	16 (47.1)	2 (5.9)		48 (70.6)	20 (29.4)
T2	192	72 (37.5)	101 (52.6)	19 (9.9)	0.509	245 (63.8)	139 (36.2)	0.280	1.36 (0.78–2.39)
T3	51	15 (29.4)	28 (54.9)	8 (15.7)	0.161	58 (56.9)	44 (43.1)	0.070	1.82 (0.95–3.51)
T4	25	6 (24.0)	18 (72.0)	1 (4.0)	0.156	30 (60.0)	20 (40.0)	0.230	1.60 (0.74–3.45)
Lymph node
N0	157	55 (35.0)	87 (55.4)	15 (9.6)		197 (62.7)	117 (37.3)
N1	107	48 (44.9)	51 (47.7)	8 (7.5)	0.270	147 (68.7)	67 (31.3)	0.167	0.77 (0.53–1.12)
N2	38	6 (15.8)	25 (65.8)	7 (18.4)	0.042a	37 (48.7)	39 (51.3)	0.024a	1.78 (1.08–2.95)
Metastasis
M0	285	103 (36.1)	156 (54.7)	26 (9.1)	0.142	362 (63.5)	208 (36.5)	0.371	1.37 (0.68–2.76)
M1	17	6 (35.3)	7 (41.2)	4 (23.5)		19 (55.9)	15 (44.1)
Clinical stage
I + II	223	90 (40.4)	113 (50.7)	20 (9.0)	0.033a	193 (55.8)	153 (44.2)	0.986	0.99 (0.68–1.46)
III + IV	79	19 (24.1)	50 (63.3)	10 (12.7)		88 (55.7)	70 (44.3)

Notes:

a Statistically significant.

Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval.